8-K: Acrivon Therapeutics Announces Positive Phase 2b Trial Results and Third Quarter 2024 Financials

Acrivon Therapeutics reported positive clinical data for its ACR-368 drug in endometrial cancer, with a 62.5% overall response rate, and provided a business update for the third quarter of 2024.

Summary

• Acrivon Therapeutics announced its third quarter 2024 financial results and provided business updates.
• The company reported a net loss of $22.4 million for the quarter ended September 30, 2024, compared to a net loss of $14.5 million for the same period in 2023.
• Research and development expenses were $18.9 million for the quarter, up from $10.3 million in the same period of 2023, due to the continued development of ACR-368 and the initiation of the ACR-2316 clinical trial.
• General and administrative expenses were $6.3 million for the quarter, compared to $5.9 million in the same period of 2023.
• As of September 30, 2024, Acrivon had $202.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2026.
• The company presented positive interim data from its Phase 2b study of ACR-368 in endometrial cancer, showing a confirmed overall response rate of 62.5% in patients with high-grade endometrial cancer.
• The ACR-368 OncoSignature patient selection was further validated with a p-value of 0.009.
• The company completed planned enrollment of the first dose-escalation cohort in the Phase 1 study of ACR-2316.
• Acrivon is evaluating options to potentially move ACR-368 into the front-line setting for endometrial cancer.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data for ACR-368, a strong cash position, and rapid advancement of ACR-2316. While there are increased losses, the overall tone is optimistic and suggests a positive outlook for the company.

Positives

• The 62.5% overall response rate for ACR-368 in endometrial cancer is a very promising result.
• The statistical significance of the OncoSignature patient selection (p=0.009) further validates the company's AP3 platform.
• The company has a strong cash position of $202.8 million, providing a runway into the second half of 2026.
• The rapid advancement of ACR-2316 into a Phase 1 trial demonstrates the efficiency of the AP3 platform.
• The company is exploring options to move ACR-368 into the front-line setting for endometrial cancer, which could significantly expand its market potential.

Negatives

• The company reported a net loss of $22.4 million for the quarter, an increase from $14.5 million in the same period last year.
• Research and development expenses have increased significantly, reflecting the costs of clinical trials and drug development.
• The company is still in the clinical stage and has not yet generated revenue from product sales.

Risks

• The company is dependent on the success of its clinical trials, particularly for ACR-368 and ACR-2316.
• Clinical trial results may not be consistent with earlier findings, and regulatory approvals are not guaranteed.
• The company may need to raise additional capital in the future to fund its operations.
• The competitive landscape in oncology is intense, and other companies may develop competing therapies.
• The company's AP3 platform is novel and may not achieve its full potential.

Future Outlook

The company expects to provide program updates from the ongoing Phase 2b trial of ACR-368 in the first half of 2025 and report initial data from the Phase 1 clinical study of ACR-2316 in the second half of 2025. They also plan to advance a new cell cycle drug discovery program towards development candidate nomination in 2025.

Management Comments

• Our team continues to deliver impressive progress advancing a pipeline of differentiated clinical stage therapies, said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
• We continue to believe endometrial cancer provides the first potential approval opportunity for ACR-368.

Industry Context

The positive results for ACR-368 in endometrial cancer are significant given the limited treatment options in the second-line setting after the recent approval of anti-PD-1 and chemotherapy as front-line therapy. The company's AP3 platform and its ability to predict patient response could be a differentiator in the precision medicine space.

Comparison to Industry Standards

• The reported 62.5% ORR for ACR-368 in endometrial cancer is significantly higher than the 14.7% ORR reported for chemotherapy in the second-line setting (Makker et al; N Engl J Medicine, 2022).
• The median progression-free survival of 3.8 months for chemotherapy in the second-line setting is also a benchmark that ACR-368 will be compared against.
• Companies like GSK (Zejula) and AstraZeneca (Lynparza) have established standards in the treatment of ovarian cancer, and Acrivon's ACR-368 is being developed with a similar approach of using biomarkers to identify patients most likely to respond.
• The rapid advancement of ACR-2316 into a Phase 1 trial in 15 months is faster than the industry average for drug development, highlighting the efficiency of Acrivon's AP3 platform.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and the company's financial position.
• Employees may be motivated by the progress of the company's clinical programs.
• Patients with endometrial cancer may benefit from the development of ACR-368 as a new treatment option.
• The company's suppliers and partners may see increased business opportunities as the company advances its clinical programs.

Next Steps

• The company will provide program updates from the ongoing Phase 2b trial of ACR-368 in the first half of 2025.
• The company will report initial data from the Phase 1 clinical study of ACR-2316 in the second half of 2025.
• The company will advance a new cell cycle drug discovery program towards development candidate nomination in 2025.

Key Dates

Keywords

Acrivon Therapeutics, ACR-368, ACR-2316, Endometrial Cancer, OncoSignature, AP3 Platform, Clinical Trial, Precision Medicine, Phase 2b, Phase 1, WEE1/PKMYT1 inhibitor, Biopharmaceutical, Oncology